CEO Change Under Court Receivership: New CEO Appointed as Part of Rehabilitation Plan - Company in Financial Distress
The CEO has been changed from Jeong Geun-ho to Seong Gwang-hyeon following the approval of the rehabilitation plan by the Seoul Bankruptcy Court.
New CEO Seong Gwang-hyeon has experience as Vice President at Bukwang Pharmaceutical and Managing Director at OCI Holdings, but the company remains under court receivership with high financial uncertainty.
This change does not involve any capital adjustments or shareholder return policies; the primary focus is on restoring operational stability.
[AI Summary]Union Korea Pharm is attempting to normalize management by replacing the CEO under court-led rehabilitation, but investors face continued high uncertainty and financial risk.